Insilico opens Pandomics box for AI target discovery

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Insilico announces Pandomics, an AI-powered hypothesis generation engine that interprets OMICS and text-based data for the discovery and analysis of new therapeutic targets.

Insilico is busy, busy, busy. In just a few months it has partnered with Arctoris in a robotics/AI partnership, spun-out Deep Longevity (which then launched Young.AI, having previously just been acquired by Regent Pacific) and teamed up with Intel for a new COVIDomic platform.

Longevity.Technology: Insilico Medicine began work on an engine for target identification back in 2014. Since then, it has had several successful partnering initiatives with pharma and research organisations as well as its own drug development programmes.

Pandomics aims to be bamboozingly successful as the go-to platform for biologists and clinicians, who will be able to use a variety of OMICS datasets, analysing, interpreting and visualising data in order to classify patient cohorts more accurately. Leveraging this potent AI to discover and develop drugs that target aging could make significant improvements to Longevity outcomes.

Today Insilico announced Pandomics, a part of the Pharma.ai platform which is designed to boost pharmaceutical target and drug discovery pipelines.

 


 

“We also collaborated with dozens of key opinion leaders in different disease areas to complete experimental validation of Pandomics …”

 


 

Research biologists and clinicians will be able to use Pandomics to perform OMICS data analytics and interpretation without requiring any prior knowledge of computational biology or bioinformatics, Insilico said. In addition, drug target identification and biomarker development specialists will be able to use the AI platform to generate hypotheses and assess repositioning strategies.

Pandomics targets metrics and is able to assemble publication data on a gene, including patents, news, publications and articles, as well as showing whether these instances are increasing or decreasing, indicating whether the scientific community is saturated with information, or whether there are areas still left to explore. The contexualised knowledge links genes and diseases and, according to today’s press briefing, is an “evolution of AI tools – a pandomics revolution.”

“At Insilico, we have developed a platform that hands the power of bioinformatics over to the researcher’s hands. Biologists, clinicians and therapeutic target specialists, will gain a wide range of novel visual ways to interpret biological data. When designing the tool, we focused on storytelling in data analysis and providing guidance for each step.” said Alexey Dubovenko, Product Director for Pandomics at Insilico Medicine.

Scientists from Harvard and Insilico have used thousands of whole genome sequencing samples from gut bacteria to develop a new deep microbiomic aging clock
Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.

“We recently used parts of the Pandomics platform in combination with Chemistry42, our generative chemistry platform and inClinico, our clinical trials prediction platform, to demonstrate that we can go from the nomination of disease of interest to novel disease targets, to compounds that are ready to enter IND-enabling studies in record time,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine.

He added: “We also collaborated with dozens of key opinion leaders in different disease areas to complete experimental validation of Pandomics. We are very happy to put this system into the hands of research scientists, drug discovery and development experts, and medical doctors interested in research and academic publishing.”

Image credit: G4889166 / Pixabay
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Deep learning platform seeks near-term indications of age-related diseases

Arrive co-founder talks combining aging cell biology, drug screening and deep learning technology in the quest to discover novel antiaging targets. Silicon Valley and Singapore-based...

Shooting for the moon means going down the rabbit hole

Scientific co-operation, research collaboration and alternative financial incentives – Moon Rabbit is a crypto-conglomerate on a longevity mission. Moon Rabbit is on a mission to...

At-home blood test powers personalised longevity advice

AgeRate develops proprietary DNA methylation clock and mobile app solution to offer users personalised longevity support. Canadian startup AgeRate is aiming to shake up the...

A new approach to reversing tissue aging

Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging. Last year, a startup called Revel Pharmaceuticals emerged from the labs at Yale...